[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"State University of New York at Buffalo\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":618},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,56,0,25,[9,46,76,101,118,141,172,200,222,241,265,276,305,334,361,386,405,427,447,467,487,512,536,557,586],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":21,"enrollmentInfo":22,"targetDuration":4,"studyType":25,"phases":26,"briefSummary":28,"conditions":29,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100053753","pairs-friend-based-aisa-intervention-100053753",false,"NCT07433270","PAIRS: Friend-Based AISA Intervention","Friend-based Intervention to Reduce Alcohol-Involved Sexual Assault Risk","PAIRS","Inclusion Criteria:\n\n* Women\n* 4 or more drinks in a single sitting 2 or more times monthly in the past 3 months\n* does not live at home with parents\n* reports going out (not necessarily drinking) with the other member of their dyad \\> 1\u002Fweek\n\nExclusion Criteria:\n\n* Can not speak and understand English sufficiently",true,"FEMALE","18 Years","24 Years",{"count":23,"type":24},560,"ESTIMATED","INTERVENTIONAL",[27],"NA","This Phase 2 trial will to examine the efficacy of a brief dyad-based motivational interview (PAIRS MI) delivered to friend dyads with an active treatment-as-usual condition, and a 1-year follow-up.",[30,31,32],"Sexual Violence","College Drinking","Behavioral Changes","RECRUITING","2026-07-09",{"date":36,"type":37},"2026-07-13","ACTUAL",{"date":39,"type":37},"2026-05-06",{"date":41,"type":24},"2030-08-01",{"name":43,"class":44},"State University of New York at Buffalo","OTHER",1,{"id":47,"slug":48,"hasResults":12,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":12,"sex":52,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":25,"phases":57,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":45},"100590275","ai-enhanced-app-based-intervention-for-adolescent-e-cigarette-cessation-100590275","NCT06965296","AI-Enhanced App-based Intervention for Adolescent E-cigarette Cessation","Inclusion Criteria\n\n* Adolescents who are 14 to 20 years old\n* Currently use nicotine-containing e-cigarettes (those responding \"Yes\" to: Have you used an electronic vaping product such as PuffBar, ElfBar, Lost Mary, JUUL, Vuse, e-cigarettes, vapes, vape pens, e-cigars, e-hookahs, hookah pens, or mods at least 1 day in the last 30 days? \\[CDC, 2020\\])\n* Interested in participating in an e-cigarette use cessation program\n* Owners of an iPhone or Android smartphone who use their phone daily\n* Able to read English\n\nExclusion Criteria\n\n* Individuals who fall outside the age range of 14 to 20 years\n* Those who have not used a nicotine-containing e-cigarette in the past 30 days\n* Individuals not interested in participating in an e-cigarette cessation program\n* Adolescents who do not own or regularly use an iPhone or Android smartphone\n* Non-English speakers","ALL","14 Years","20 Years",{"count":56,"type":24},100,[27],"The goal of this quasi-experimental study is to test if a smartphone app can help adolescents aged 14-20 quit e-cigarettes. The main questions it aims to answer are:\n\n* Can the app help adolescents manage cravings and increase their readiness to quit?\n* Does the personalized and real-time support provided by the app improve their success in quitting e-cigarettes?\n\nResearchers will compare two groups: an immediate-intervention group that starts using the app right away and a delayed-intervention group that begins after three months, to see if the timing of app access influences outcomes in e-cigarette cessation.\n\nParticipants will:\n\n* Set personal goals and track their daily progress within the app.\n* Use a real-time \"urge\" feature that provides immediate support during cravings.\n* Engage with a chatbot for quick answers and motivational support around quitting.\n\nThis study aims to create an accessible, personalized tool to help adolescents reduce or quit e-cigarette use, exploring its feasibility as a broader intervention model.",[60],"Nicotine Dependence, Cigarettes",[62,63,64,65,66],"Adolescent e-cigarette use","E-cigarette cessation","Smartphone app","Digital health intervention","Personalized health support","NOT_YET_RECRUITING","2026-06-30",{"date":70,"type":37},"2026-07-02",{"date":72,"type":24},"2026-08-01",{"date":74,"type":24},"2027-06-30",{"name":43,"class":44},{"id":77,"slug":78,"hasResults":12,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":18,"sex":52,"minAge":20,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":25,"phases":85,"briefSummary":86,"conditions":87,"keywords":91,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":4},"100596481","work-design-interventions-for-older-workers-during-consecutive-days-in-the-heat-100596481","NCT07046026","Work Design Interventions for Older Workers During Consecutive Days in the Heat","Inclusion Criteria:\n\n* Healthy individuals\n* 18-29 years old and 40-65 years old\n* Completes at least 120 minutes of moderate to vigorous physical activity each week for at least the past 4 weeks\n* Resistance trained or have recently held a job involving box carrying or a similar task\n\nExclusion Criteria:\n\n* History of cardiovascular, metabolic, respiratory, neural, or renal disease\n* Hypertensive (systolic blood pressure \\> 139 mmHg or diastolic blood pressure \\> 89 mmHg) or tachycardic (resting heart rate \\> 100 bpm) during the screening visit\n* Current nicotine use or previous use within the past 6 months\n* Current of previous musculoskeletal injury limiting physical activity\n* A positive pregnancy test at any point during the study\n* Currently breastfeeding\n* Study physician discretion based on any other medical condition or medication","65 Years",{"count":84,"type":24},32,[27],"The goal of this project is to compare different ways to schedule a workday to see if older workers should follow a specific work protocol to reduce strain on the heart and muscles across two consecutive days of work.\n\nParticipants will come to the lab a total of six times. During four of the visits participants will complete a box carrying task, simulating unloading a delivery truck. This will take place in a hot and humid room to simulate being outdoors during the summer.",[88,89,90],"Hyperthermia","Fatigue; Heat","Work-Related Condition",[92,93],"hyperthermia","worker","2026-06-26",{"date":68,"type":37},{"date":97,"type":24},"2028-09",{"date":99,"type":24},"2030-09",{"name":43,"class":44},{"id":102,"slug":103,"hasResults":12,"nctId":104,"briefTitle":105,"officialTitle":105,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":18,"sex":52,"minAge":20,"maxAge":82,"enrollmentInfo":106,"targetDuration":4,"studyType":25,"phases":107,"briefSummary":108,"conditions":109,"keywords":110,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":112,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":4},"100562178","work-design-interventions-for-heat-resilience-100562178","NCT06599788","Work Design Interventions for Heat Resilience",{"count":84,"type":24},[27],"The goal of this project is to compare different ways to schedule a workday to see if older workers should follow a specific work protocol to reduce strain on the heart and muscles.\n\nParticipants will come to the lab a total of six times. During four of the visits participants will complete a box carrying task, simulating unloading a delivery truck. This will take place in a hot and humid room to simulate being outdoors during the summer.",[88,89,90],[92,93,111],"fatigue",{"date":68,"type":37},{"date":114,"type":24},"2027-09",{"date":116,"type":24},"2029-09",{"name":43,"class":44},{"id":119,"slug":120,"hasResults":12,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":124,"eligibilityCriteria":125,"healthyVolunteers":18,"sex":52,"minAge":126,"maxAge":127,"enrollmentInfo":128,"targetDuration":4,"studyType":25,"phases":130,"briefSummary":131,"conditions":132,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":45},"100509056","the-early-childhood-friendship-project---phase-3-100509056","NCT05908461","The Early Childhood Friendship Project - Phase 3","The Early Childhood Friendship Project: Testing Key Mechanisms and the Moderating Role of Physiological Reactivity","ECFP-3","Inclusion Criteria:\n\n* A child is eligible if attending one of the participating child care centers in the greater Buffalo region of Western New York and planning to enter kindergarten in the fall.\n\nExclusion Criteria:\n\n* None","4 Years","6 Years",{"count":129,"type":24},600,[27],"The purpose of this study is to assess the impact of the Early Childhood Friendship Project (ECFP) on changes in aggression\u002Fpeer victimization subtypes, prosocial behavior, and social and academic competence with a teacher-implemented (with coaching) version of the program. Further, investigators will examine whether changes in executive functioning, emotion regulation, and hostile attribution biases indirectly account for the program effects. Investigators will test if physiological reactivity (skin conductance and respiratory sinus arrhythmia) serves as moderators of intervention effects. Data will be collected from 600 children (30 randomly assigned preschool classrooms) diverse in socioeconomic status and race\u002Fethnicity. Investigators will use multiple methods (school-based observations, direct academic assessments, child interviews, physiological reactivity using two tasks, observer, caregiver, and teacher reports) to assess the efficacy of the program, hypothesized mechanisms, and role of physiology as a moderator of intervention effects. The duration of the effects will be tested at both 4 month and 12-month follow-up and will thus demonstrate the impact the program has on children's school readiness and transition to kindergarten. It is expected that preschool children randomly assigned to the ECFP intervention relative to the control condition will show significant and moderate reductions in physical and relational aggression\u002Fvictimization at post-test and follow-up; the ECFP intervention group will also show increases in prosocial behavior, social competence, and academic competence, relative to the control group at post-test and follow-up (4-months at the end of preschool and 12 months after transitioning to kindergarten). Additionally, it is hypothesized that changes in executive functioning, emotion regulation, and hostile attribution biases will mediate treatment effects from baseline to respective follow-ups. It is anticipated that these hypothesis will be moderated by gender such that effects will be stronger for girls relative to boys. Finally, it is hypothesized that physiological reactivity will act as a moderator of intervention effects and of the executive functioning, emotion regulation, and hostile attribution biases mechanisms.",[133],"Healthy","2026-06-25",{"date":68,"type":37},{"date":137,"type":37},"2023-08-16",{"date":139,"type":24},"2027-04-16",{"name":43,"class":44},{"id":142,"slug":143,"hasResults":12,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":147,"eligibilityCriteria":148,"healthyVolunteers":18,"sex":52,"minAge":20,"maxAge":149,"enrollmentInfo":150,"targetDuration":4,"studyType":25,"phases":152,"briefSummary":153,"conditions":154,"keywords":158,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":171,"locationsCount":45},"100636430","examining-migration-social-bonds-transnationalism-and-hiv-prevention-pathways-among-african-immigrants-100636430","NCT07565584","Examining Migration, Social Bonds, Transnationalism, and HIV Prevention Pathways Among African Immigrants.","Migration, Social Bonds, Transnationalism, and HIV Prevention Pathways Among African Immigrants (MiST-Pathways)","MiST-Pathways","Inclusion Criteria: Individuals must meet ALL of the following criteria:\n\n* Age 18 to 50 years at the time of enrollment\n* Self-identify as a first-generation African immigrant (born in an African country and currently residing in the United States)\n* Currently reside in New York or Massachusetts\n* Able to communicate in English at approximately a 3rd-grade reading level\n* Have access to a smartphone or computer with internet capability sufficient to participate in Zoom and\u002For WhatsApp-based study activities\n* Willing and able to provide informed consent\n\nExclusion Criteria:\n\n* Are under 18 years of age\n* Do not self-identify as a first-generation African immigrant\n* Do not reside in New York or Massachusetts\n* Are unable to provide informed consent\n* Do not have access to the technology required for virtual participation (Zoom and\u002For WhatsApp)","50 Years",{"count":151,"type":24},144,[27],"The goal of this mixed-methods pilot study is to learn whether migration experiences, social bonds, and transnational ties shape HIV prevention decision-making, including HIV testing, HIV self-testing (HIVST), and pre-exposure prophylaxis (PrEP) uptake, among first-generation African immigrants aged 18 to 50 residing in New York and Massachusetts. The main questions it aims to answer are:\n\n* What relationship typologies and migration-related relational mechanisms influence HIV testing, HIVST, and PrEP decision-making among African immigrants?\n* Can a relationship-tailored HIV prevention intervention component, co-developed with the community, demonstrate feasibility and acceptability among African immigrants?\n* Does exposure to the prioritized intervention component show directional increases in HIV testing intention, willingness to use HIVST, interest in PrEP, and readiness for relationship-based prevention communication? There is no comparison group. All Aim 3 participants receive the same co-developed intervention component.\n\nParticipants will:\n\n* Complete a qualitative interview (60-90 minutes) and\u002For a structured electronic survey (15-20 minutes) about their relationship experiences, migration history, and HIV prevention behaviors.\n* Take part in a 3-4 hour structured group deliberation session called a Palava Hut Conversation to co-develop and prioritize HIV prevention intervention ideas.\n* Complete a baseline survey, receive the prioritized intervention component in a structured Zoom session, and complete a follow-up survey with an optional 60-90 minute cognitive interview for a subset of participants.",[155,156,157],"HIV Prevention","HIV Testing","Sexual and Reproductive Health",[159,160,161,162,163,155,164],"HIV selt-testing (HIVST)","Pre-exposure prophylaxis (PrEP)","African immigrants","Transnationalism","Relationship Typologies","Palava Hut Conversations","2026-06-24",{"date":167,"type":37},"2026-06-29",{"date":169,"type":24},"2026-08-04",{"date":114,"type":24},{"name":43,"class":44},{"id":173,"slug":174,"hasResults":12,"nctId":175,"briefTitle":176,"officialTitle":177,"acronym":4,"eligibilityCriteria":178,"healthyVolunteers":12,"sex":52,"minAge":126,"maxAge":179,"enrollmentInfo":180,"targetDuration":4,"studyType":25,"phases":182,"briefSummary":183,"conditions":184,"keywords":187,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":45},"100557530","project-asthma---aligning-with-schools-to-help-manage-asthma-and-improve-outcomes-100557530","NCT06539312","Project ASTHMA - Aligning With Schools To Help Manage Asthma and Improve Outcomes","Project ASTHMA - Aligning With Schools To Help Manage Asthma and Decrease Health Inequities","Inclusion Criteria:\n\n* uncontrolled asthma\n\nExclusion Criteria:\n\n* other chronic lung disease such as cystic fibrosis","13 Years",{"count":181,"type":24},400,[27],"Children with asthma from communities that experience health inequities frequently do not receive guideline-based asthma care, and as a result, account for a disproportionate percentage of asthma exacerbations, emergency department visits, and hospitalizations. Project ASTHMA (Aligning with Schools To Help Manage Asthma) tests the effectiveness of school-based health centers as a delivery model to improve health outcomes by providing children with guideline-based asthma assessments and preventive medication management, directly observed therapy of their preventive medication to support adherence, and self-management support. If successful, this multicomponent intervention will represent a cost effective and sustainable model to reduce asthma morbidity in historically marginalized communities, and has the potential to impact communities throughout the United States where over 2,500 school-based health centers operate.",[185,186],"Asthma in Children","Directly Observed Therapy",[188,189,190,191,192,186],"Asthma","Children","School-based health center","NIH Guideline-based care","Controller medication","2026-06-22",{"date":134,"type":37},{"date":196,"type":37},"2024-09-27",{"date":198,"type":24},"2028-04-30",{"name":43,"class":44},{"id":201,"slug":202,"hasResults":12,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":4,"eligibilityCriteria":206,"healthyVolunteers":18,"sex":52,"minAge":20,"maxAge":207,"enrollmentInfo":208,"targetDuration":4,"studyType":25,"phases":210,"briefSummary":211,"conditions":212,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":45},"100626744","comparison-of-root-canal-desinfection-protocols-100626744","NCT07439614","Comparison of Root Canal Desinfection Protocols","Comparison of Different Root Canal Disinfection Protocols for Bacterial Reduction in Teeth With Apical Periodontitis Using Two Analytical Microbiological Methods: a Randomized Clinical Study","Inclusion Criteria:\n\n* Adult patients able to give informed consent and willing\u002Fable to comply with study procedures and follow-up.\n* Molar teeth indicated for endodontic treatment.\n* Teeth with intact pulp-chamber walls (no extensive coronal destruction).\n* Necrotic pulp confirmed by pulp testing.\n* Clinical and radiographic evidence of asymptomatic apical periodontitis.\n\nExclusion Criteria:\n\n* Immature teeth\n* Teeth with calcified or obliterated canals\n* Teeth with extensive coronal destruction\n* Teeth with previous endodontic treatment\n* Symptomatic apical periodontitis\n* Teeth with periodontal pockets greater than 4 mm\n* Patients who have received systemic antibiotics in the last 3 months\n* Patients with a history of diabetes or immune impairment\n* Pregnant patients","70 Years",{"count":209,"type":24},50,[27],"Evaluate and compare the disinfecting efficacy of two supplementary antimicrobial protocols in teeth with apical periodontitis",[213],"Periapical Periodontitis","2026-06-18",{"date":216,"type":37},"2026-06-23",{"date":218,"type":37},"2026-04-01",{"date":220,"type":24},"2027-06",{"name":43,"class":44},{"id":223,"slug":224,"hasResults":12,"nctId":225,"briefTitle":226,"officialTitle":226,"acronym":4,"eligibilityCriteria":227,"healthyVolunteers":12,"sex":52,"minAge":20,"maxAge":4,"enrollmentInfo":228,"targetDuration":230,"studyType":231,"phases":4,"briefSummary":232,"conditions":233,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":235,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":45},"100277944","non-invasive-liver-screening-using-fibroscan-device-for-liver-disease-patients-for-the-steatosisfibrosis-database-100277944","NCT02897908","Non-invasive Liver Screening Using FibroScan Device for Liver Disease Patients for the Steatosis\u002FFibrosis Database","Inclusion Criteria:\n\n* Subjects with known, or suspected risk factors for steatosis (fat) or hepatic fibrosis\n* Subjects who have been previously diagnosed with Non-Alcoholic Steatohepatitis (NASH) but who do not have current steatosis (fat) or fibrosis scoring\n* Subjects who have other known liver diseases ie: HCV\n\nExclusion Criteria:\n\n* Patients less than 18 years of age\n* Pregnancy\n* Patients that do not want to be contacted for consideration in future research studies.\n* Patients diagnosed with ascites or peritoneal dialysis\n* Body mass index (BMI) ≥40",{"count":229,"type":24},1000,"1 Day","OBSERVATIONAL","The primary goal of this study is to establish a database of people with varying levels of hepatic fibrosis and various etiologies of liver disease for use in future research protocols.",[234],"Disease of Liver and Bile Duct",{"date":193,"type":37},{"date":237,"type":37},"2016-10-28",{"date":239,"type":24},"2027-04",{"name":43,"class":44},{"id":242,"slug":243,"hasResults":12,"nctId":244,"briefTitle":245,"officialTitle":245,"acronym":4,"eligibilityCriteria":246,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":247,"targetDuration":4,"studyType":25,"phases":249,"briefSummary":250,"conditions":251,"keywords":254,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":259,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":264,"locationsCount":45},"100641755","prevention-of-postpartum-smoking-relapse-and-related-health-consequences-by-breastfeeding-promotion-100641755","NCT07661550","Prevention of Postpartum Smoking Relapse and Related Health Consequences by Breastfeeding Promotion","Inclusion Criteria:\n\n* Be pregnant\n* Be 18 years or older\n* Have quit smoking cigarettes during this pregnancy\n* Be willing to receive infant care and breastfeeding education\n* Be able to read, listen, and talk in English\n\nExclusion Criteria:\n\n* Medical conditions contraindicating breastfeeding, such as HIV infection, active tuberculosis, and breast removal\n* Current heavy drinking (≥4 standard drinks on any day or ≥8 standard drinks per week)",{"count":248,"type":24},280,[27],"The objective of this randomized controlled trial is to examine the efficacy of a new intervention to prevent postpartum smoking relapse and related health consequences through breastfeeding promotion. After the pre-test, ex-smokers who are still abstinent from smoking will be randomized into either the breastfeeding intervention or the attention placebo control group. The outcomes are postpartum smoking relapse, breastfeeding practices, and maternal and child health.",[252,253],"Smoking ( Cigarette)","Breastfeeding",[255,256,257],"Pregnancy","Postpartum","Relapse","2026-06-16",{"date":193,"type":37},{"date":261,"type":37},"2026-01-01",{"date":263,"type":24},"2031-07-31",{"name":43,"class":44},{"id":266,"slug":4,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":21,"enrollmentInfo":267,"targetDuration":4,"studyType":25,"phases":268,"briefSummary":28,"conditions":269,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":271,"startDateStruct":272,"completionDateStruct":273,"leadSponsor":275,"locationsCount":45},"100626256",{"count":23,"type":24},[27],[30,31,32],"2026-06-15",{"date":258,"type":37},{"date":39,"type":37},{"date":274,"type":24},"2030-08",{"name":43,"class":44},{"id":277,"slug":278,"hasResults":12,"nctId":279,"briefTitle":280,"officialTitle":281,"acronym":4,"eligibilityCriteria":282,"healthyVolunteers":12,"sex":52,"minAge":283,"maxAge":284,"enrollmentInfo":285,"targetDuration":4,"studyType":25,"phases":287,"briefSummary":288,"conditions":289,"keywords":293,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":297,"lastUpdatePostDateStruct":298,"startDateStruct":300,"completionDateStruct":302,"leadSponsor":304,"locationsCount":45},"100642886","impact-of-vns-with-rehab-on-gait-post-stroke-100642886","NCT07643337","Impact of VNS With Rehab on Gait Post-Stroke","The Impact of Vagus Nerve Stimulation Paired With Rehabilitation on Lower Limb and Gait Functions After Ischemic Stroke","Inclusion Criteria:\n\n* Approved for Vagus Nerve Stimulation (VNS) and rehabilitation therapy\n* ≥22 years and ≤ 80 years\n* Only patients who elect to undergo VNS therapy for stroke-related upper limb deficits\n* Residual active movement in the affected limb's thumb and other 2 fingers\n* Stroke-related deficits in the lower limbs and gait with a Functional Ambulation Category (FAC) ≥3\n* Able to follow simple instructions and independently walk short distances with or without external support or leg orthoses, but without manual contact with another person\n\nExclusion Criteria:\n\n* Intact lower limb functions (Fugl-Meyer score=34)\n* Not a candidate for VNS therapy according to FDA guidelines\n* Pregnant patients","22 Years","80 Years",{"count":286,"type":24},24,[27],"This is a prospective, double-blinded, randomized controlled study to evaluate the impact of Vagus Nerve Stimulation (VNS) therapy on lower limb function.",[290,291,292],"Upper Limb Deficit","Stroke Gait Rehabilitation","Stroke",[294,295,296],"vagus nerve stimulation","stroke rehabilitation","stroke related upper limb deficit","2026-06-08",{"date":299,"type":37},"2026-06-11",{"date":301,"type":24},"2026-06",{"date":303,"type":24},"2028-02-23",{"name":43,"class":44},{"id":306,"slug":307,"hasResults":12,"nctId":308,"briefTitle":309,"officialTitle":310,"acronym":4,"eligibilityCriteria":311,"healthyVolunteers":12,"sex":52,"minAge":20,"maxAge":312,"enrollmentInfo":313,"targetDuration":4,"studyType":25,"phases":315,"briefSummary":316,"conditions":317,"keywords":323,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":297,"lastUpdatePostDateStruct":329,"startDateStruct":330,"completionDateStruct":331,"leadSponsor":333,"locationsCount":45},"100642861","hydration-intervention-to-decrease-side-effects-associated-with-glp---1-ra-therapy-100642861","NCT07641361","Hydration Intervention to Decrease Side Effects Associated With GLP - 1 RA Therapy","Hydration Intervention to Address Dehydration Associated With Use of GLP-1 Based Medications","Inclusion Criteria:\n\n* Adults aged 18-60\n* Recently prescribed a GLP-1RA (within one week of prescription)\n* Fluent in English\n* Willing to complete the study protocol\n\nExclusion Criteria:\n\n* Children and adults \\> 60 years of age\n* Those not taking a GLP-1RA\n* Those who have been on a GLP-1RA longer than one week\n* Not fluent in English\n* Those who are pregnant or planning on becoming pregnant during the duration of the study\n* Unwilling to comply with study protocol\n* People with cardiac implants","60 Years",{"count":314,"type":24},30,[27],"This is a 17 - week study consisting of a one - week run - in period and a 16 - week intervention. The 16 - week pilot interventions aims to increase hydration in those beginning GLP - 1 RA therapy. Investigators aim to increase hydration to potentially decrease side effect severity, amount of side effects, and drug discontinuation associated with GLP - 1 RA therapy. The investigators are piloting to assess feasibility and preliminary efficacy of the intervention through examining participant retention, participant feedback, researcher and participant adherence to protocols, impact on hydration biomarkers, and participant reported GLP - 1 RA side effects.",[318,319,320,321,322],"Obesity & Overweight","Type 2 Diabetes","Type 2 Diabetes (Adult Onset)","Obesity Type 2 Diabetes Mellitus","Dehydration",[324,325,326,322,327,328],"Hydration","GLP - 1 RA","GLP - 1 RA therapy","Hydration biomarkers","GLP - 1 RA side effects",{"date":299,"type":37},{"date":270,"type":24},{"date":332,"type":24},"2027-02-01",{"name":43,"class":44},{"id":335,"slug":336,"hasResults":12,"nctId":337,"briefTitle":338,"officialTitle":339,"acronym":4,"eligibilityCriteria":340,"healthyVolunteers":12,"sex":52,"minAge":20,"maxAge":341,"enrollmentInfo":342,"targetDuration":4,"studyType":25,"phases":343,"briefSummary":344,"conditions":345,"keywords":349,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":297,"lastUpdatePostDateStruct":355,"startDateStruct":356,"completionDateStruct":358,"leadSponsor":360,"locationsCount":45},"100632361","titrated-ambulatory-oxygen-in-fibrotic-ild-and-copd-with-isolated-exertional-hypoxemia-100632361","NCT07512687","Titrated Ambulatory Oxygen in Fibrotic ILD and COPD With Isolated Exertional Hypoxemia","Impact of Ambulatory Oxygen Delivery on Real-world Activity and Quality-of-life in Patients With Interstitial Lung Disease (ILD) and Chronic Obstructive Pulmonary Disease (COPD)","Inclusion Criteria:\n\n* Adults \\>= 18 years old and \\\u003C= 85 years old with fibrotic ILD or COPD able to provide informed consent\n* Fibrotic ILD includes idiopathic pulmonary fibrosis, sarcoidosis, or other ILD with fibrotic changes on lung imaging (reticulations, honeycombing, traction bronchiectasis)\n* COPD participants will have fixed airway obstruction on spirometry less than 70%-predicted as per Global Initiative for Obstructive Lung Disease (GOLD) diagnostic criteria\n* Participants will self-report as being ambulatory outside of home without use of assistance device such as a cane or walker\n* Stable lung disease on stable medical therapy for preceding 3 months\n* Isolated exertional hypoxemia (SpO2 less than 89% for \\>=10 seconds) on a 6MWT conducted while breathing room air\n* Able to maintain SpO2 \\>=89% for the full duration of a 6MWT while using the the POC and portable oxygen D-tank at POC setting of no higher than 6 and D-tank flow rate no higher than 6 liters per minute\n\nExclusion Criteria:\n\n* People \\\u003C18 years old or \\>85 years old\n* Participants with mixed ILD and COPD diagnoses\n* Resting hypoxemia less than 89% while breathing room air\n* Emergency room visit or hospital admission in 3 months prior to recruitment\n* Change in medical therapy in 3 months prior to recruitment\n* Need for ambulatory assistive device such as cane or walker\n* Pregnant\n* Currently smoking or residing with a current smoker\n* Currently engaged in a pulmonary rehabilitation program\n* Participants without a smartphone compatible with the Oxiwear app (necessary to collect Oxiwear oxygen saturation data) or those with a compatible smartphone but without home wifi or cellular service plan allowing for Oxiwear data uploading","85 Years",{"count":286,"type":24},[27],"Fibrotic forms of interstitial lung disease (ILD) and chronic obstructive pulmonary disease (COPD) are chronic lung disease which often affect how well oxygen can get from the lungs into the blood. Low blood oxygen levels often leads to shortness of breath which can affect patients' activity levels and quality-of-life. Many people with fibrotic ILD and COPD only have low oxygen levels when they are walking or exercising. Oxygen that is only used for walking or exercise is called ambulatory oxygen therapy (AOT). Laboratory studies suggest that AOT improves shortness of breath and exercise ability. However, real-world studies of AOT have not shown similar results. AOT can be given to patients through different types of equipment, most commonly oxygen tanks or portable oxygen concentrators (POCs). While previous studies have suggested that AOT does not significantly improve patients' breathing or activity in the real-world, these studies most often gave all participants the same amount of oxygen with the same device. However, patients with ILD and COPD often have very different oxygen needs during exercise, and POCs and oxygen tanks are very different in how oxygen is administered.\n\nThis trial will test the feasibility of a study to determine whether real-world activity, symptoms, and quality-of-life are different with the use of different oxygen equipment when oxygen therapy has been adjusted to meet each participants' oxygen needs. A total of 24 participants (12 with fibrotic ILD and 12 with COPD) who only have low oxygen levels with activity will be randomly assigned to 2-week periods using either no oxygen therapy or oxygen delivered by oxygen tanks or POC. This trial will provide preliminary data to support a larger clinical trial to further test how different AOT equipment titrated to meet individual patients' needs may affect real-world outcomes in people with ILD and COPD.",[346,347,348],"Interstitial Lung Disease","Chronic Obstructive Pulmonary Disease","Hypoxemia",[350,351,352,353,354],"Ambulatory Oxygen Therapy","Portable Oxygen Concentrator","Exertional Hypoxemia","6-Minute Walk Test","Real-World Activity",{"date":299,"type":37},{"date":357,"type":24},"2026-07",{"date":359,"type":24},"2027-10",{"name":43,"class":44},{"id":362,"slug":363,"hasResults":12,"nctId":364,"briefTitle":365,"officialTitle":365,"acronym":4,"eligibilityCriteria":366,"healthyVolunteers":12,"sex":52,"minAge":149,"maxAge":4,"enrollmentInfo":367,"targetDuration":4,"studyType":25,"phases":369,"briefSummary":371,"conditions":372,"keywords":374,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":378,"lastUpdatePostDateStruct":379,"startDateStruct":381,"completionDateStruct":383,"leadSponsor":385,"locationsCount":45},"100639996","phase-2-the-effect-of-osteoporotic-medications-on-vertebral-bone-quality-score-100639996","NCT07587775","The Effect of Osteoporotic Medications on Vertebral Bone Quality Score","Inclusion Criteria:\n\n* Diagnosis of Osteoporosis based on the following criteria:\n\n  * Fragility fracture (low trauma fracture similar to a fall from a standing position except for fracture to the skull, face, fingers, and toes)\n  * T score \\\u003C-2.5\n  * T-score -1 to -2.5 with a high FRAX or high TBS adjusted FRAX (with a 10-year probability of major osteoporotic fracture ≥20% or a 10-year probability of hip fracture ≥3%)\n* Fulfill criteria for treatment with anabolic therapy, as outlined in the American Association of Clinical Endocrinologist guidelines for the diagnosis and treatment of postmenopausal osteoporosis in women and Evidence-Based Guideline for the management of osteoporosis in men.\n* Lumbar Degenerative Disease as evidenced by a diagnosis of spondylosis, spondylolisthesis, degenerative disc disease with spinal stenosis, and degenerative scoliosis\n* Have or be willing to have a DEXA scan, lumbar MRI, and lumbar CT within 3 months of the start of Abaloparatide\n* If on thyroid hormone replacement, having been on it for at least 6 months\n\nExclusion Criteria:\n\n* Previous lumbar surgery\n* Past medical history of: sarcoma, including osteosarcoma, paget disease or other skeletal malignancies, unexplained elevations of alkaline phosphatase, prior external beam radiation, and pre-existing hypercalcemia\n* Diagnosis of secondary osteoporosis\n* Vitamin D deficit\n* History of prior treatment with TPTD and ABL",{"count":368,"type":24},60,[370],"PHASE2","The goal of this clinical trial is to determine the change in VBQ score, T score, TBS, and Hounsfield Units (HU) after 3-6 months of treatment with abaloparatide in osteoporotic patients who will undergo spinal fusion and decompression for lumbar degenerative disease. The main question\\[s\\] it aims to answer is:\n\nDoes abaloparatide improve bone density in these patients, as defined by VBQ score compared to traditional methods such as DEXA and Hounsfield Units Does abaloparatide reduce the incidence of postoperative mechanical complications, including adjacent segment disease, subsidence, and proximal junctional kyphosis (PKJ)?\n\nParticipants will undergo a presurgical assessments and trained in clinic on the subcutaneous application of abaloparatide. Prior to treatment, patients will have baseline assessments, including a lumbar MRI, DEXA scan, and lumbar CT. Post-surgically, participants will administer abaloparatide and return to clinic after 3-6 months for follow-up assessments including a new MRI, lumbar CT, and DEXA scan. Patients will be followed for up to 2 years postoperatively to identify complications such as adjacent segment disease, pseudarthrosis, failure of instrumentation, and PJK.",[373],"Lumbar Degenerative Disease",[375,376,373,377],"Osteoporosis","Spinal Fusion","Abaloparatide","2026-05-12",{"date":380,"type":37},"2026-05-14",{"date":382,"type":24},"2026-06-01",{"date":384,"type":24},"2028-12-31",{"name":43,"class":44},{"id":387,"slug":388,"hasResults":12,"nctId":389,"briefTitle":390,"officialTitle":390,"acronym":4,"eligibilityCriteria":391,"healthyVolunteers":18,"sex":52,"minAge":4,"maxAge":4,"enrollmentInfo":392,"targetDuration":4,"studyType":25,"phases":394,"briefSummary":395,"conditions":396,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":398,"lastUpdatePostDateStruct":399,"startDateStruct":400,"completionDateStruct":402,"leadSponsor":404,"locationsCount":45},"100479487","comparison-of-intraocular-pressure-measurement-with-the-novel-tonovera-device-with-other-commonly-used-devices-100479487","NCT05523622","Comparison of Intraocular Pressure Measurement With the Novel TonoVera Device With Other Commonly Used Devices","Inclusion Criteria:\n\n* Ability to provide signed and dated informed consent form. Patients willing to comply with all study procedures and be available for the duration of the study.\n\nMale or female patients aged 18 to 99 Patients in good general health as evidenced by ability to come to their appointment on day of study.\n\nExclusion Criteria:\n\n* Patients age less than 18 years Patients unable or unwilling to provide informed consent to participate in the study Patients for which an accurate tonometry reading cannot be performed. This may include those with blepharospasm (lid squeezers), nystagmus, extensive corneal pathology, or contact lens wearers who cannot remove their contact lens.Patients with significant scleral thinning Patients with a known allergy to proparacaine or fluorescein as these are used to anesthetize and allow measurement respectively of the eye when used with the Goldmann tonometer.",{"count":393,"type":24},300,[27],"We are testing the accuracy of Reichert's Tono-Vera tonometer by comparing measurements of IOP with this device and measurements with other commonly-used tonometers, including Goldmann Applanation and iCare.",[397],"Glaucoma","2026-05-04",{"date":39,"type":37},{"date":401,"type":37},"2022-08-01",{"date":403,"type":24},"2027-12-31",{"name":43,"class":44},{"id":406,"slug":407,"hasResults":12,"nctId":408,"briefTitle":409,"officialTitle":410,"acronym":411,"eligibilityCriteria":412,"healthyVolunteers":12,"sex":52,"minAge":20,"maxAge":4,"enrollmentInfo":413,"targetDuration":4,"studyType":25,"phases":415,"briefSummary":416,"conditions":417,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":419,"lastUpdatePostDateStruct":420,"startDateStruct":422,"completionDateStruct":424,"leadSponsor":426,"locationsCount":45},"100603771","cgm-enhanced-dpp-to-prevent-type-2-diabetes-in-adults-with-prediabetes-100603771","NCT07140848","CGM-Enhanced DPP to Prevent Type 2 Diabetes in Adults With Prediabetes","A Novel Continuous Glucose Monitoring Enhanced DPP Intervention to Prevent Type 2 Diabetes in Adults With Prediabetes","CGM-DPP","Inclusion Criteria:\n\n1. adults aged 18 years or older,\n2. diagnosis of prediabetes, as defined by current clinical guidelines (HbA1c 5.7% to 6.4%, fasting plasma glucose 100-125 mg\u002FdL, or 2-hour plasma glucose 140-199 mg\u002FdL following a 75g oral glucose tolerance test),\n3. body mass index (BMI) of at least 24 kg\u002Fm² (or 22 kg\u002Fm² for Asian Americans),\n4. willingness to comply with all aspects of the study protocol, including attending coaching sessions and using CGM devices.\n\nExclusion Criteria:\n\nIndividuals will be excluded from the study if they\n\n1. have a diagnosis of type 1 or type 2 diabetes,\n2. are currently using CGMs or have medical contraindications to CGM use, such as severe skin allergies or implantable defibrillators, or\n3. are currently enrolled in another clinical trial for prediabetes. Additionally, using validated assessments, we will exclude participants with significant dementia, alcohol or drug abuse\u002Fdependency, active psychosis, or life expectancy less than 12 months as these conditions are likely to interfere with adherence to the intervention.",{"count":414,"type":24},214,[27],"Prediabetes affects over one-third of adults in the United States, placing them at a higher risk for developing type 2 diabetes and heart disease, which can lead to serious health complications and increased medical costs. Although a program called the Diabetes Prevention Program (DPP) has been shown to lower the risk of diabetes through healthy lifestyle changes, many people find it difficult to stick with these changes over the long term. This study seeks to find out if combining DPP coaching with continuous glucose monitoring (CGM) technology can help people stay on track with their health goals.",[418],"PreDiabetes","2026-04-21",{"date":421,"type":37},"2026-04-24",{"date":423,"type":37},"2026-04-13",{"date":425,"type":24},"2028-03",{"name":43,"class":44},{"id":428,"slug":429,"hasResults":12,"nctId":430,"briefTitle":431,"officialTitle":432,"acronym":4,"eligibilityCriteria":433,"healthyVolunteers":18,"sex":52,"minAge":20,"maxAge":434,"enrollmentInfo":435,"targetDuration":4,"studyType":25,"phases":437,"briefSummary":438,"conditions":439,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":441,"lastUpdatePostDateStruct":442,"startDateStruct":444,"completionDateStruct":445,"leadSponsor":446,"locationsCount":45},"100626309","neuromodulation-to-improve-grasping-function-after-sci-100626309","NCT07433959","Neuromodulation to Improve Grasping Function After SCI","Neuromodulation to Improve Grasping Function After Spinal Cord Injury","Inclusion Criteria:\n\nFor individuals with SCI:\n\n* Ages 18-75 years\n* Chronic SCI (≥1 year of injury)\n* Cervical injury at C8 or above\n* Individuals who have MEP responses in at least one FDI muscle\n\nExclusion Criteria:\n\n* Uncontrolled medical problems including pulmonary or cardiovascular disease\n* Premorbid, ongoing major depression or psychosis, altered cognitive status\n* History of head injury or stroke\n* Metal plate in skull\n* History of seizures\n* Receiving drugs acting primarily on the central nervous system, which lower the seizure threshold such as antipsychotic drugs\n* Pregnant females\n* Individuals who suffer from a spinal cord disease such as spinal stenosis, spinal bifida or herniated cervical","75 Years",{"count":436,"type":24},54,[27],"The goal of this study is to restore the activities of late descending signals with a noninvasive stimulation approach in combination with hand motor training to improve hand function in persons with cervical SCI. The main question it aims to answer is if the inputs to late descending signals above the level of injury and the output of residual late descending signals below the level of injury could be increased. Specifically, in the first part of the study, 30 participants will complete 2 randomized sessions to compare the effect of intermittent theta burst stimulation combined with paired corticospinal motoneuronal stimulation. In the second part of the study, 24 participants will complete either combined stimulation protocol or sham stimulation protocol with exercise training.",[440],"Spinal Cord Injury","2026-04-20",{"date":443,"type":37},"2026-04-23",{"date":218,"type":37},{"date":74,"type":24},{"name":43,"class":44},{"id":448,"slug":449,"hasResults":12,"nctId":450,"briefTitle":451,"officialTitle":452,"acronym":453,"eligibilityCriteria":454,"healthyVolunteers":18,"sex":52,"minAge":20,"maxAge":21,"enrollmentInfo":455,"targetDuration":4,"studyType":25,"phases":457,"briefSummary":458,"conditions":459,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":441,"lastUpdatePostDateStruct":462,"startDateStruct":463,"completionDateStruct":465,"leadSponsor":466,"locationsCount":45},"100613064","collaborative-opportunities-for-reducing-alcohol-and-sexual-violence-together-100613064","NCT07261722","Collaborative Opportunities for Reducing Alcohol and Sexual Violence Together","Harnessing the Power of Military Peers to Reduce Sexual Violence and Risky Drinking in Service Members","COAST","Inclusion Criteria:\n\n* Enlisted U.S. Navy service members on active duty status\n* Meet criteria for risky drinking (i.e. score of 4+ for men, 2+ for women according to the AUDIT-C)\n* Have an eligible peer and the pair must socialize together at least twice a month\n\nExclusion Criteria:\n\n* Individuals who endorse evidence of withdrawal (Item 6 on the AUDIT)",{"count":456,"type":24},132,[27],"The goal of this clinical trial is to test if a modified peer-based motivational intervention (the Military PAIRS; MPAIRS) is reasonable and practical for military contexts. The main questions it aims to answer are:\n\n* Does it works to reduce SV?\n* Does it works to reduce risky drinking? To test this, participants will answer questions about their SV history and risky drinking. Then they will be given MPAIRS. After 1 month, they will be asked about their SV history and risky drinking again.",[30,460,461],"Behavior Change","Military Training",{"date":443,"type":37},{"date":464,"type":37},"2025-10-10",{"date":239,"type":24},{"name":43,"class":44},{"id":468,"slug":469,"hasResults":12,"nctId":470,"briefTitle":471,"officialTitle":472,"acronym":4,"eligibilityCriteria":473,"healthyVolunteers":12,"sex":474,"minAge":20,"maxAge":4,"enrollmentInfo":475,"targetDuration":4,"studyType":25,"phases":476,"briefSummary":477,"conditions":478,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":480,"lastUpdatePostDateStruct":481,"startDateStruct":483,"completionDateStruct":485,"leadSponsor":486,"locationsCount":45},"100529323","intermittent-fasting-in-prostate-cancer-patients-receiving-androgen-deprivation-therapy-100529323","NCT06172283","Intermittent Fasting in Prostate Cancer Patients Receiving Androgen Deprivation Therapy","A Pilot, Feasibility Study of Intermittent Fasting in Prostate Cancer Patients Receiving Androgen Deprivation Therapy","Inclusion Criteria:\n\n* In order to be eligible for participation in this trial, the subject must:\n* Be willing and able to provide written informed consent for the trial.\n* Be male at birth and least 18 years of age on day of signing informed consent.\n* Have measurable prostate cancer disease and be eligible for androgen deprivation therapy.\n* Have a performance status of 0-2 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale.\n* Demonstrate adequate organ function (all screening labs should be performed within 10 days of treatment initiation).\n* Subjects have archival tumor tissue available or are willing to undergo a baseline biopsy prior to treatment.\n* Subjects must have a life expectancy of at least 6 months.\n\nExclusion Criteria:\n\n* Has an ECOG performance of 2 or higher.\n* Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the beginning of the treatment.\n* Has a known additional malignancy that is progressing or requires active treatment.\n* Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.\n* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n* Has a known allergy, intolerance, or medical contraindication to receiving the contrast dye required for the protocol-specified CT\u002FMRI imaging\n* Has any other medical intervention or condition which, in the opinion of the Principal Investigator, could compromise adherence with study requirements or otherwise compromise the study's objectives.\n* Is not willing and able to provide written informed consent for the trial.","MALE",{"count":314,"type":24},[27],"This is a a pilot study to assess the feasibility of intermittent caloric restriction (plus a plant-enriched diet optionally) in prostate cancer patients receiving androgen deprivation therapy. Study feasibility measures will include enrollment rate, drop-out rate and compliance with diet measured by self-reports.",[479],"Prostate Cancer","2026-04-17",{"date":482,"type":37},"2026-04-22",{"date":484,"type":37},"2023-12-05",{"date":384,"type":24},{"name":43,"class":44},{"id":488,"slug":489,"hasResults":12,"nctId":490,"briefTitle":491,"officialTitle":491,"acronym":4,"eligibilityCriteria":492,"healthyVolunteers":18,"sex":52,"minAge":493,"maxAge":4,"enrollmentInfo":494,"targetDuration":4,"studyType":25,"phases":495,"briefSummary":497,"conditions":498,"keywords":500,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":504,"lastUpdatePostDateStruct":505,"startDateStruct":507,"completionDateStruct":509,"leadSponsor":511,"locationsCount":45},"100525990","phase-4-the-role-of-neutrophils-in-the-age-driven-decline-in-anti-pneumococcal-vaccine-responses-100525990","NCT06128915","The Role of Neutrophils in the Age-driven Decline in Anti-pneumococcal Vaccine Responses","Inclusion Criteria:\n\n* Both sexes\n* Have not been vaccinated with any licensed or experimental pneumococcal vaccine\n* Ages 21-40; and ≥65. Individuals \\>60 years old will also be recruited in case we find no unvaccinated people ≥65 years old\n* Free of acute infections within the last 2 weeks\n* Did not take any anti-inflammatory medicine in the last week\n* Did not ingest alcohol in the last 24 hours\n* Ability and willingness to provide consent\n\nExclusion Criteria:\n\n* Previous vaccination with any licensed or experimental pneumococcal vaccine\n* Known hypersensitivity to vaccination and vaccine components\n* Immune deficiency\n* Use of immune-modulating or suppressive drugs\n* Malignancies within the last 2 years\n* Known hematological, rheumatic and inflammatory diseases\n* Known chronic infections\n* Poorly controlled chronic cardiovascular and metabolic conditions\n* Pregnancy\n* Dementia","21 Years",{"count":368,"type":24},[496],"PHASE4","This study focuses on the role of neutrophils in shaping the adaptive immune response to the anti-pneumococcal vaccine Prevnar-13 in young and elderly adults.",[499],"Aging",[499,501,502,503],"Neutrophils","Streptococcus pneumoniae","Pneumococcal conjugate vaccine","2026-04-02",{"date":506,"type":37},"2026-04-03",{"date":508,"type":37},"2024-01-08",{"date":510,"type":24},"2027-05-31",{"name":43,"class":44},{"id":513,"slug":514,"hasResults":12,"nctId":515,"briefTitle":516,"officialTitle":516,"acronym":4,"eligibilityCriteria":517,"healthyVolunteers":12,"sex":52,"minAge":20,"maxAge":4,"enrollmentInfo":518,"targetDuration":4,"studyType":25,"phases":519,"briefSummary":520,"conditions":521,"keywords":525,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":529,"lastUpdatePostDateStruct":530,"startDateStruct":531,"completionDateStruct":533,"leadSponsor":535,"locationsCount":45},"100466626","a-pilot-and-feasibility-study-of-a-dietary-intervention-with-low-protein-meals-in-cancer-patients-receiving-immunotherapies-100466626","NCT05356182","A Pilot and Feasibility Study of a Dietary Intervention With Low-protein Meals in Cancer Patients Receiving Immunotherapies","Inclusion Criteria:\n\n* Histologically documented solid tumor malignancies which is amenable for immunotherapy treatment with immune checkpoint inhibitors (i.e. PD1, PD-L1, CTLA inhibitors) as single agents or in combination.\n* Metastatic disease as evidenced by soft tissue and\u002For bony metastases on baseline bone scan and\u002For computed tomography (CT) scan of the chest, abdomen, and pelvis\n* Life expectancy of at least 6 months\n* Adults ≥ 18 years of age\n* Adequate hematologic, renal, and liver function as evidenced by the following:\n\n  * White blood cell (WBC) ≥ 2,500 cells\u002FμL\n  * Absolute neutrophil count (ANC) ≥ 1,000 cells\u002FμL\n  * Platelet Count ≥ 100,000 cells\u002FμL\n  * Hemoglobin (HgB) ≥ 9.0 g\u002FdL\n  * Creatinine ≤ 2.0 mg\u002FdL\n  * Total bilirubin ≤ 2 x upper limit of normal (ULN)\n  * Aspartate aminotransaminase (AST, SGOT) ≤ 2.5 x ULN\n  * Alanine aminotransaminase (ALT, SGPT) ≤ 2.5 x ULN\n\nExclusion Criteria:\n\n* • Eastern Cooperative Oncology Group (ECOG) performance status 2 or higher\n\n  * Treatment with any of the following medications or interventions within 28 days of registration:\n\n    * Systemic corticosteroids; however, use of inhaled, intranasal, and topical steroids is acceptable.\n    * High dose calcitriol \\[1,25(OH)2VitD\\] (i.e., \\> 7.0 μg\u002Fweek)\n  * A requirement for systemic immunosuppressive therapy for any reason\n  * Any infection requiring parenteral antibiotic therapy or causing fever (temperature \\> 100.5°F or 38.1°C) within 1 week prior to registration\n  * A known allergy, intolerance, or medical contraindication to receiving the contrast dye required for the protocol-specified CT imaging\n  * Any medical intervention or other condition which, in the opinion of the Principal Investigator, could compromise adherence with study requirements or otherwise compromise the study's objectives",{"count":314,"type":24},[27],"The main idea of this study is that a low protein diet may alter the environment surrounding the tumor, enhancing the body's immune response leading to greater anticancer effects of treatment. This study intends to use a low-protein diet as a tool to enhance the immune response generated by immune check point inhibitor treatments.",[522,523,524],"Medical Oncology","Integrative Oncology","Medical Nutrition Therapy",[526,527,528],"Oncology","Nutrition","Immunotherapy","2026-03-30",{"date":506,"type":37},{"date":532,"type":37},"2022-05-04",{"date":534,"type":24},"2028-02",{"name":43,"class":44},{"id":537,"slug":538,"hasResults":12,"nctId":539,"briefTitle":540,"officialTitle":541,"acronym":4,"eligibilityCriteria":542,"healthyVolunteers":12,"sex":52,"minAge":20,"maxAge":4,"enrollmentInfo":543,"targetDuration":4,"studyType":25,"phases":545,"briefSummary":547,"conditions":548,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":550,"lastUpdatePostDateStruct":551,"startDateStruct":552,"completionDateStruct":554,"leadSponsor":556,"locationsCount":45},"100533190","phase-1-study-to-evaluate-the-safety-and-efficacy-of-bicalutamide-in-combination-with-sunitinib-in-patients-with-tkis-resistant-rcc-100533190","NCT06222593","Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination With Sunitinib in Patients With TKIs-resistant RCC","A Phase I\u002FII Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination With Sunitinib in Patients With Receptor Tyrosine Kinase Inhibitor Resistant Renal Cell Carcinoma","Inclusion Criteria:\n\n1. Be willing and able to provide written informed consent for the trial.\n2. Be greater than or equal to 18 years of age on day of signing informed consent.\n3. Have measurable disease based on RECIST 1.1\n4. Have a performance status of 0-2 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale\n5. Demonstrate adequate organ function\n6. Female subject of childbearing potential should have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication.\n7. Subjects of childbearing potential should be willing to use 2 methods of contraception for the course of the study through 120 days after the last dose of study medication\n8. Male subjects without a previous vasectomy should agree to use an adequate method of contraception (i.e. abstinence, condom with spermicidal foam\u002Fgel\u002Ffilm\u002Fcream) starting with the first dose of study therapy through 120 days after the last dose of study therapy.\n9. Subjects have archival tumor tissue available or are willing to undergo a baseline biopsy prior to treatment.\n10. Subjects must have a life expectancy of at least 6 months.\n\nExclusion Criteria:\n\n1. Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.\n2. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.\n3. Has active Bacillus tuberculosis (TB)\n4. Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer.\n5. Has known active central nervous system (CNS) metastases and\u002For carcinomatous meningitis.\n6. Has an active infection requiring systemic therapy.\n7. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.\n8. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n9. Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment.\n10. Has a known history of Human Immunodeficiency Virus (HIV)\n11. Has known active Hepatitis B or Hepatitis C\n12. Has received a live vaccine within 30 days of planned start of study therapy",{"count":544,"type":24},28,[546,370],"PHASE1","This is a Phase I\u002FII open-label, efficacy and safety study of bicalutamide in combination with sunitinib in patients with advanced renal cell carcinoma (RCC) who have been treated with a receptor tyrosine kinase inhibitor (RTKI) and experienced disease progression.",[549],"Carcinoma, Renal Cell","2026-03-26",{"date":218,"type":37},{"date":553,"type":37},"2024-10-01",{"date":555,"type":24},"2027-07-01",{"name":43,"class":44},{"id":558,"slug":559,"hasResults":12,"nctId":560,"briefTitle":561,"officialTitle":562,"acronym":4,"eligibilityCriteria":563,"healthyVolunteers":12,"sex":52,"minAge":564,"maxAge":127,"enrollmentInfo":565,"targetDuration":4,"studyType":25,"phases":566,"briefSummary":567,"conditions":568,"keywords":573,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":578,"lastUpdatePostDateStruct":579,"startDateStruct":581,"completionDateStruct":583,"leadSponsor":585,"locationsCount":45},"100554927","picu-related-sleep-and-circadian-dysregulation-pilot-study-100554927","NCT06505447","PICU-related Sleep and Circadian Dysregulation Pilot Study","A Three-phase Pilot Study of the Feasibility of the Measurement and Promotion of Sleep and the Circadian Rhythm in a Pediatric Intensive Care Unit","Inclusion Criteria:\n\n1. Child age 3 to 6 years old on the day of PICU admission\n2. English-speaking parent at the bedside\n3. Child expected to remain in the PICU over 24 to 48 hours\n\nExclusion Criteria:\n\n1. Child is in end-of-life care\n2. The child is receiving neuromuscular blockade for any reason\n3. Caregiver or parent not at the bedside","3 Years",{"count":314,"type":24},[27],"A single center pilot trial investigating the feasibility of using actigraphy and salivary melatonin levels to measure the sleep and circadian rhythm of critically ill children aged 3 to 6 years old. This study will also measure the feasibility of providing daytime light exposure as well as restricting all provided nutrition to during daytime hours.",[569,570,571,572],"Circadian Dysrhythmia","Sleep Disturbance","Critical Illness","Children, Only",[574,575,576,577],"Sleep disruption","circadian rhythm","critical care","pediatrics","2026-03-18",{"date":580,"type":37},"2026-03-23",{"date":582,"type":37},"2024-12-06",{"date":584,"type":24},"2027-01-01",{"name":43,"class":44},{"id":587,"slug":588,"hasResults":12,"nctId":589,"briefTitle":590,"officialTitle":591,"acronym":4,"eligibilityCriteria":592,"healthyVolunteers":18,"sex":52,"minAge":312,"maxAge":4,"enrollmentInfo":593,"targetDuration":4,"studyType":25,"phases":595,"briefSummary":596,"conditions":597,"keywords":600,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":610,"lastUpdatePostDateStruct":611,"startDateStruct":613,"completionDateStruct":615,"leadSponsor":617,"locationsCount":45},"100596831","group-recreation-to-enhance-function-aging-100596831","NCT07050589","Group Recreation to Enhance Function Aging","A Community-Based Recreation Program to Improve Function and Quality of Life in Older Adults","Inclusion Criteria\n\n* \\> = 60 years of age\n* have no more than MCI (MoCA score ≥ 24 points)\n* have no contraindications to exercise, guided by the American College of Sports Medicine\n* fluent in English\n\nExclusion Criteria\n\n* have a condition that would prevent safe participation in the exercise, as determined by the Physical Activity Readiness Questionnaire for Older Adults (PAR-OA);\n* have severe neurological disease\n* have severe psychiatric illness\n* have a likelihood of withdrawing from the study due to severe illness or a life expectancy of \\\u003C 6 mo\n* have experienced a lower or upper limb amputation\n* have greater than mild cognitive impairment (MoCA score \\\u003C 24 points).",{"count":594,"type":24},80,[27],"Investigators will develop and deliver a community-based recreation program, delivering group artmaking and group SMARTfit dual-task exergaming to community-dwelling older adults. The program will be delivered through the Buffalo-Niagara YMCA. Outcomes of interest are change in cognitive function and change in physical functioning, inresponse to 24 weeks of weekly training.",[598,599],"Physical Functioning","Cognitive Functioning",[601,602,603,604,605,606,607,608,609],"walking","balance","strength","attention","memory","interference inhibition","dual-task","artmaking","exergaming","2026-03-13",{"date":612,"type":37},"2026-03-16",{"date":614,"type":37},"2025-09-15",{"date":616,"type":24},"2026-07-15",{"name":43,"class":44},""]